In a new webcast, Sarepta Therapeutics said it will seek approval for and start a confirmatory trial of eteplirsen in 2014; additional drugs may follow

posted on October 18, 2013 - 2:31pm
Sarepta Therapeutics announced it is on track to submit an application to the U.S. Food and Drug Administration (FDA) for approval of eteplirsen in the first half of 2014. In parallel with that application, the company is preparing to conduct a large-scale, confirmatory trial of eteplirsen. It plans to open the trial during the first quarter of 2014.
posted on October 1, 2009 - 10:11am
QUEST Vol. 16, No. 4
The following story includes items about: Becker muscular dystrophy, centronuclear myopathy, type 1A Charcot-Marie-Tooth disease, congenital muscular dystrophy, Duchenne muscular dystrophy, limb-girdle muscular dystrophy, Miyoshi myopathy (distal muscular dystrophy), type 1 myotonic muscular dystrophy, myotubular myopathy, nemaline myopathy, and spinal muscular atrophy